---
schema_version: "secwatch.filing_event.v1"
accession: "0001485003-23-000089"
form_type: "8-K"
ticker: "CARM"
cik: "0001485003"
company_name: "Carisma Therapeutics Inc."
filed_at: "2023-02-28T23:59:59+00:00"
generated_at: "2026-06-18T21:50:50.501235+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Sesen Bio reports Q4 net loss $7.6M; reiterates support for Carisma merger ahead of shareholder vote

## Summary
- Q4 net loss $7.6M ($0.04/shr) vs net income $8.9M in Q4 2021; FY net loss $19.9M ($0.10/shr).
- Cash, equivalents and marketable securities $166.9M as of Dec 31, 2022.
- Board increased special cash dividend to $75M (~$0.36/shr) under amended merger with Carisma; CVR period extended to Mar 2027.
- ISS and Glass Lewis recommend voting 'FOR' all merger proposals at Mar 2, 2023 special meeting.
- Nasdaq granted exception from $1.00 bid price requirement to complete merger by Mar 10, 2023 or face delisting.

## SEC filing metadata
- accession: 0001485003-23-000089
- form_type: 8-K
- ticker: CARM
- cik: 0001485003
- company_name: Carisma Therapeutics Inc.
- filed_at: 2023-02-28T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1485003/000148500323000089/0001485003-23-000089-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1485003/000148500323000089/sesn-20230228.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001485003-23-000089
- JSON: https://secwatch.observer/filing/0001485003-23-000089.json
- Plain text: https://secwatch.observer/filing/0001485003-23-000089.txt

## Key facts
- Earnings Releases
  Carisma Therapeutics Inc. reported financial results for the fourth quarter and full year ended December 31, 2022.
  - Period: the fourth quarter and full year ended December 31, 2022
  - Result: reported results
  source text: Sesen Bio (Nasdaq: SESN) today reported operating results for the fourth quarter and full year ended December 31, 2022, and provided a business update.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1485003/000148500323000089/0001485003-23-000089-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.